Wolfgang C Korte
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Albrich W, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi J, Brand S. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2023; 58:678-691.
Aug 12, 2023STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Aug 12, 2023Aliment Pharmacol Ther 2023; 58:678-691
Woelfel Simon, Dütschler Joel, König Marius, Dulovic Alex, Graf Nicole, Junker Daniel, Oikonomou Vasileios, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Eckhold Annika, Forsch Kristina, Koller Seraina, Wyss Jacqueline, Krupka Niklas, Oberholzer Melanie, Frei Nicola Fabian, Geissler Nora, Schaub Peter, STAR SIGN Study Investigators, Albrich Werner, Friedrich Matthias, Schneiderhan-Marra Nicole, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Friedrich M, Misselwitz B, Korte W, Bürgi J, Brand S. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. Aliment Pharmacol Ther 2022; 57:103-116.
Oct 28, 2022Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Oct 28, 2022Aliment Pharmacol Ther 2022; 57:103-116
Woelfel Simon, Dütschler Joel, König Marius, Graf Nicole, Oikonomou Vasileios, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Eckhold Annika, Forsch Kristina, Wyss Jacqueline, Krupka Niklas, Albrich Werner, Frei Nicola Fabian, Geissler Nora, Schaub Peter, STAR SIGN Study Investigators, Friedrich Matthias, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood
Jámbor C, Reul V, Schnider T, Degiacomi P, Metzner H, Korte W. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood. Anesthesia and analgesia 2009; 109:1023-8.
Oct 1, 2009In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood
Oct 1, 2009Anesthesia and analgesia 2009; 109:1023-8
Jámbor Csilla, Reul Viviane, Schnider Thomas, Degiacomi Priska, Metzner Hubert, Korte Wolfgang C
Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding
Korte W, Lange J, Devay J, Zoller N, Degiacomi P, Eder M, Kownacki E, Gabi K, Gähler A, Szadkowski C, Schnider T. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009; 110:239-45.
Feb 1, 2009Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding
Feb 1, 2009Anesthesiology 2009; 110:239-45
Korte Wolfgang C, Lange Jochen, Devay Jan, Zoller Norbert, Degiacomi Priska, Eder Monika, Kownacki Edward, Gabi Konrad, Gähler Anita, Szadkowski Christine, Schnider Thomas